{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108876","form_type":"8-K","ticker":"TYRA","cik":"0001863127","company_name":"Tyra Biosciences, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.428456+00:00","generated_at":"2026-05-17T13:28:10.561627+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Tyra Biosciences Q2 2025 cash $296.3M; dosed first patient in SURF302 NMIBC trial","bullets":["Cash, cash equivalents and marketable securities of $296.3M as of June 30, 2025; runway through at least 2027.","Q2 net loss of $28.1M, vs $18.7M in Q2 2024; R&D expenses $24.3M (up from $18.0M).","Dosed first patient in SURF302 Phase 2 study of dabogratinib for FGFR3-altered intermediate-risk NMIBC.","BEACH301 Phase 2 achondroplasia study now enrolling safety sentinel cohort; dose first child expected 3Q 2025.","Initial three-month complete response data from SURF302 expected in first half 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108876","json":"https://secwatch.observer/filing/0000950170-25-108876.json","markdown":"https://secwatch.observer/filing/0000950170-25-108876.md","text":"https://secwatch.observer/filing/0000950170-25-108876.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/0000950170-25-108876-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1863127/000095017025108876/tyra-20250814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:28:10.561627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}